BioPorto A/S Ownership
| THOXF Stock | USD 0.29 0.02 6.45% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BioPorto |
BioPorto Pink Sheet Ownership Analysis
About 20.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.03. BioPorto A/S had not issued any dividends in recent years. BioPorto AS, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company was founded in 2000 and is headquartered in Hellerup, Denmark. Bioporto operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 29 people.The quote for BioPorto AS is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about BioPorto AS contact the company at 45 45 29 00 00 or learn more at https://bioporto.com.Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in BioPorto Pink Sheet
BioPorto A/S financial ratios help investors to determine whether BioPorto Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioPorto with respect to the benefits of owning BioPorto A/S security.